Drug Profile
L 159913
Alternative Names: L-159,913Latest Information Update: 14 Jul 1998
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 14 Jul 1998 No-Development-Reported for Hypertension in USA (Unknown route)
- 31 Aug 1995 Preclinical development for Hypertension in USA (Unknown route)